GH Synergy Stack

Ask the pituitary twice and it answers louder than twice. That receptor-level quirk — GHRH and ghrelin signals multiplying each other's effect rather than simply adding — is the entire premise of the GH Synergy Stack, which pairs Sermorelin, a synthetic 29-amino-acid analogue of growth hormone-releasing hormone that stimulates GH in a physiological, pulsatile pattern mirroring endogenous hypothalamic signaling [PMID: 18031173], with Ipamorelin, a selective ghrelin-receptor agonist notable for releasing GH without elevating cortisol or prolactin — the spillover that complicated older secretagogues [PMID: 9849822].

The numbers give the pairing teeth. Co-activating both receptor systems produced intracellular cAMP roughly twice the GHRH-alone response [PMID: 12446584], and in human studies even low-dose ghrelin stimulated GH release synergistically with GHRH administration [PMID: 11549707]. For anyone weighing research approaches against injecting growth hormone outright, the distinction matters: this stack persuades the body to release its own hormone, in rhythm.

Ahead you'll find the receptor pharmacology behind the multiplication, the clinical data each compound carries separately, and the conspicuous absence of combination trials. Both compounds remain research peptides; the synergy evidence is mechanistic, not clinical — a line this page holds firmly from start to finish.

Sermorelin's clinical file is the deeper of the two. In elderly men, administration increased 24-hour mean GH, peak GH, and IGF-1 — one 16-week study reporting GH increases up to 107%, accompanied by corresponding IGF-1 elevation [PMID: 9141536]. The same research documented lean body mass gains (1.26 kg in men) and increased skin thickness, consistent with a revived GH-IGF-1 axis [PMID: 9141536]. Crucially, release stays pulsatile: the pituitary keeps its rhythm rather than drowning in sustained supraphysiological levels [PMID: 18046908].

Ipamorelin contributes precision. Acting at GHSR-1a via phospholipase C activation and intracellular calcium signaling [PMID: 9849822], it released GH with potency rivaling GHRP-6 while leaving ACTH, cortisol, and prolactin untouched even at 200-fold doses — the Raun et al. selectivity finding that made its reputation [PMID: 9849822]. Pharmacokinetic modeling adds the right shape: a single GH episode peaking near 0.67 hours with exponential decline — a pulse, not a plateau [PMID: 10496658].

Then comes the arithmetic of synergy. Co-activation of GHRH and GHS receptors doubles the cAMP response relative to GHRH alone [PMID: 12446584], because two cascades — adenylyl cyclase versus phospholipase C and diacylglycerol — converge on GH vesicle exocytosis from different sides of the cell. Human data agrees in spirit: sub-threshold ghrelin doses produced synergistic GH release when combined with GHRH [PMID: 11549707].

What's still missing is the obvious experiment: no clinical trial has tested sermorelin plus ipamorelin together. Until one does, this pairing stands on elegant receptor pharmacology and two respectable individual dossiers — a strong foundation that is still not the building.

Both peptides go under the skin, but their pharmacokinetics set different clocks. Sermorelin clears in 12–15 minutes and is commonly studied at 200–500 mcg per injection, once or twice daily; research suggests twice-daily dosing raises IGF-1 significantly better than once-nightly administration, making frequency a genuine experimental variable rather than a detail [PMID: 32257855]. Each subcutaneous injection produces a rapid GH pulse within 15–30 minutes.

Ipamorelin typically appears at 200–300 mcg per injection, one to three times daily. Its roughly two-hour half-life keeps the resulting GH episode transient — a feature researchers value precisely because it preserves physiological pulsatility instead of sustained elevation [PMID: 9849822].

Single-secretagogue protocols have been explored across 4 to 16 weeks. For combinations, the literature splits: some researchers describe co-administering both peptides simultaneously for maximal synergistic pulses, others stagger injections to create more frequent GH episodes across the day. No consensus protocol exists for the specific combination, and all available information reflects preclinical models, receptor pharmacology studies, or limited human data on individual compounds — the honest baseline beneath every question below.